CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018 Providence News Team

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute:

Study: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006) for B-cell non-Hodgkin lymphoma

JCAR017 is an investigational CAR T-cell therapy that modifies a patient’s own T-cells to express proteins called CARs (chimeric antigen receptors), which help T-cells recognize tumor cells and go after them. A Phase I study of JCAR017 in people with aggressive forms of B-cell lymphoma found that it provided “a durable reduction or eradication of cancer,” including complete cancer eradication in just over half of the patients. Read more in Lymphoma News Today.

CAR T-cell therapy is a major research priority for the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center. Read more about JCAR017 in Immuno-Oncology News, and find out more about adoptive T-cell therapy research at Providence.

Providence is one of only two centers in the United States currently participating in this clinical trial. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614. Call us early for consideration, before the patient receives a salvage therapy or stem cell transplant.

See more studies
New research studies are added frequently. Please visit our website to see all studies in all cancer types currently open at Providence Cancer Institute.

Enter content here

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

About the Author

Previous Article

Next Article

Other content in this Stream

Providence Portland placed second in the world during the international Babies With Books read-a-thon. Meet the nurse who helped make the achievement possible.

Lindsay Moore, Ph.D., speaks to KATU’s “AM Northwest” about finding purpose and satisfaction, while aging healthily during retirement.

Jaye found more than nutrition education at Providence's Community Teaching Kitchen. She found confidence, connection and support for lasting change.

Learn about the new Providence SAFE Center, now open in Hillsboro, and watch news coverage of the community partnership that's easing the way for survivors of violence and abuse.

Their extraordinary commitment will create Oregon’s first-ever women’s health hospital and launch the next generation of pioneering heart care.

Providence Oregon and Devoted Health to offer Medicare Advantage coverage options for people seeking continued access to Providence physicians, clinics and hospitals beginning in 2027.

If you’ve been putting off your mammogram because you’re unsure what to expect, knowing what happens during the appointment may help you feel more prepared.

For years, Lori struggled to find answers, until her gynecologist referred to Providence Center for Weight Management.

Medicare enrollment doesn't have to feel overwhelming. Learn the differences between Original Medicare and Medicare Advantage and find trusted, local resources to help you make coverage decisions.

You don't need to be an insurance expert. Taking time to review your doctors, health needs and costs can help you narrow your options and identify plans that help keep your Providence care.

Watch a news story honoring the Providence MS center's major milestone and learn more about Dr. Stanley Cohan's legacy.

Michael Potter, M.D., a sports medicine physician at Providence Medford, outlines the symptoms of carpal tunnel syndrome and offers simple treatment options.

Providence Cancer Institute is enrolling patients in a clinical trial to test Mo-Rez.

See photos from our 44th annual Providence Hood To Coast and Portland To Coast relays.

The Timbers visited caregivers and patients during their 12th annual Rose City Road Trip. See photos from their stop at Providence Portland.

Providence Cancer Institute dietitian answers questions and offers helpful tips.

Many people with advanced NSCLC still need better treatment options. This study is evaluating an investigational medication that may help them live longer.

Health plans can change each year. Use open enrollment to compare options, review costs and make sure your Providence care team is covered.

Residents and caregivers celebrated Assisted Living Week with animal-themed activities, special visitors and plenty of safari fun.

Choosing a health insurance plan is about more than cost alone. It's about finding coverage that supports your health, your budget and access to care you can trust.